



**Pre-Prion2007 CWD Workshop, Edinburgh, Tuesday 25th
September 2007, 11.00 - 18.00 Venue - South Hall**

NeuroPrion Cervids Working Group - member's meeting 9:15am – 10:45am

CHRONIC WASTING DISEASE (CWD) WORKSHOP

11.00-11.10 **Mick Stack** NeuroPrion cervid working group coordinator.
Welcome, introduction, and brief overview of the NeuroPrion cervid working group activities

SESSION I: Chronic Wasting Disease in North America:

Chair: Dr Katherine O'Rourke

11:10 – 11:30 **Dr Michael Samuel**, Wisconsin Cooperative Wildlife Research Unit, University of Wisconsin-Madison. **Chronic wasting disease in Wisconsin white-tailed deer: Is there a practical solution?**

11:30 – 11:50 **Dr Aru Balachandran** National Reference Laboratory for scrapie and CWD, Canadian Food Inspection Agency (CFIA), Ottawa, Ontario, Canada. **Chronic wasting disease in Canada: An update on distribution and ongoing research projects**

11.50 -12.10: coffee

Chair: Dr Aru Balachandran

12.10-12.30: **Dr Terry Spraker**, Department of Pathology, College of Veterinary Medicine, Colorado State University, Fort Collins, USA.
A review and up date for chronic wasting disease in North America

12:30 – 12:50 **Dr Delwyn Keane**, University of Wisconsin **CWD in a Captive White-tailed Deer Farm**

13.00-14.00: lunch

Chair: Dr Terry Spraker

14:00-14:20 **Dr Christina Sigurdson**, University Hospital Zurich. **Prion Protein Loop Region (Amino Acids 165-175) Directs Species Barriers**

14:20-14:40 **Prof Glen Telling**, University of Kentucky **Modeling prion transmission barriers using transgenic and in vitro approaches**

14:40 – 15:00 **Dr Timothy Kurt**, Colorado State University **Enhanced Detection of PrP^{CWD} by Serial Protein Misfolding Cyclic Amplification**

15:00 – 15:20 **Dr Candace Mathiason**, Colorado State University. **Additional bioassay studies to detect CWD prions in saliva, blood, and excreta of deer**

15:20-15:40 Tea

SESSION II: Results from North American & UK experimental transmission studies

Chair: Dr Jan Langeveld

15:40-16:00 **Dr Katherine O'Rourke**, USDA Pullman Washington State **Prolonged Incubation Time and Differential Processing of PrP-CWD in Experimentally Infected Rocky Mountain Elk Lacking the 132M Prnp Allele**

16:00 – 16:20 **Mr Stuart Martin** VLA Lasswade **IHC and WB Characterisation of Experimental BSE and CWD in Red Deer**

SESSION III: Results of proficiency testing in 2007

Chair: Mick Stack

16:20- 16:40 **Dr Paul Webb** VLA IHC UK **Chronic Wasting Disease – Results of PrP Immunohistochemistry Proficiency Testing 2007**

16:40 – 16:50 **Mrs Melanie Chaplin** VLA Weybridge **Results of the Community Reference Laboratory proficiency testing of rapid tests in European laboratories to detect CWD**

16.50- 17:00 Final discussions and Close

NeuroPrion Coordinator: Michael James Stack, Molecular, Pathogenesis and Genetics Department, Veterinary Laboratories Agency (VLA), Woodham Lane, Addlestone, Surrey, KT15 3NB United Kingdom, **E-mail:** m.j.stack@vla.defra.gsi.gov.uk

The University of Edinburgh




Accommodation Services

Email: accommodation@ed.ac.uk
 www.accom.ed.ac.uk

Edinburgh First

Email: EdinburghFirst@ed.ac.uk
 www.EdinburghFirst.com
 Phone: 0131 651 2189
 Fax: 0131 667 7271

Pollock Halls of Residence




Useful phone numbers

Visit Scotland: 0131 332 2433
 City Cabs: 0131 228 6876
 Lothian Buses info: 0131 555 6363
 First Edinburgh bus info: 08708 72 72 71
 Rail enquiries: 08457 48 49 50

Edinburgh Airport: 0131 333 1000
 British Airways (reservations): 08708 50 98 50
 British Airways (flight info): 0870 55 111 55
 British Midland Airways: 0870 60 70 555
 KLM UK: 08705 074 074

Pollock Halls and other University of Edinburgh accommodation locations



Accommodation site codes

DH	David Horn House	SCS	South Clerk Street	ROB	Robertson's Close
KI	Kitchener House	BLC	Blackwood Crescent	KIC	Kincaid's Court
MC	Mylne's Court	CAU	Causewayside	COL	College Wynd
RI	Richmond Place	ENP	East Newington Place	MOC	Morgan Court
WAR	Warrender Park Road	HEC	Hermit's Croft		
WAC	Warrender Park Crescent	WMA	West Mains Road		
SCI	Sciennes	DAC	Darroch Court		
SCP	Sciennes Place	NAR	New Arthur Place		

Prion Risk 2007 will be held at the City Chambers Business Centre, a central location along the scenic Royal Mile. Registration is **now open** and space is very limited – to register, please fill out the registration form available at www.prioNetCanada.ca/register/settings_list.aspx.

For all information regarding this Prion Disease Risk Management workshop, please visit PrioNet Canada's [Prion Risk 2007 website](http://www.prioNetCanada.ca) for updated event details.

Overview

BSE and other prion diseases have been detected in at least 22 other countries around the world distributed across Asia, Europe, North America, and the Middle East. A fundamental problem of past attempts to address BSE as a human health, animal health, economic and social risk issue has been due to a lack of traceability and surveillance stemming from an incomplete approach to risk management of the disease. Important additions to past practices in managing prion disease risks have included (1) a broader range of inputs (extending beyond traditional agricultural and veterinary scientists to include social scientists, economists, political scientists, and risk policy analysts), (2) analysis of a broader and longer range of impacts, extending well beyond the agricultural sector including trade, (3) inclusion of societal values and ethics reflecting public concerns about prion disease risks, and (4) improved risk communication with more complete, accurate and transparent dissemination of information on the risks of BSE not only between government departments but also between government and the private sector.

Risk management, as currently practiced by governments and international agencies around the world, has two different aspects: a *retrospective* aspect, that is, a scientific assessment of risk factors based on accumulated knowledge from the past; and a *prospective* aspect, that is, using this information for risk reduction, and the management options for realizing this objective, going forward. With reference to the prospective aspect of risk management, the crucial aspect is deciding *when* to invest in consequence-reduction strategies and *how much* to invest in any particular case. The risk assessment results obtained as part of the integrated risk management framework can be compared against the estimated costs of investments in risk reduction, with future costs appropriately discounted, in order to assess the level of need for consequence-reduction strategies. Our belief is that, in specific circumstances, early investments in risk reduction strategies may have very large payoffs in terms of averted costs.

The goal of the proposed PrioNet Canada all day break-out session is to share Canadian expertise in risk management of BSE and other prion diseases. Under PrioNet Canada Theme 5 attempts to integrate research, basic science, and social science into policy making in an integrated fashion. PrioNet Theme 5's approach is to advance the understanding of emerging risk issues and to identify methods and approaches for assessment and/or management of prion diseases. The target audience includes international scientific experts, policy makers, industry leaders and public interest stakeholders.



Tuesday, September 25, 2007:

Time	
8:30	<p>Introduction</p> <p>Neil Cashman, University of British Columbia Scientific Director, <i>PrioNet Canada</i></p> <p>8:45 Daniel Krewski, University of Ottawa <i>BSE in Canada</i></p>
9:15	<p>Prion Disease Risk Management in Canada Session Chair: Daniel Krewski, University of Ottawa</p> <p>Rob McNabb, Canadian Cattlemen's Association <i>Industry Perspectives and Recovery from the Canadian BSE Crisis</i></p> <p>9:45 Maura Ricketts, Public Health Agency of Canada <i>BSE, CJD and Public Health in Canada</i></p>
10:15 – 10:30	Break
10:30	<p>Socio-economic Impacts of BSE Session Chair: Carol Amaratunga, University of Ottawa</p> <p>Carol Amaratunga, University of Ottawa <i>Farm Community Impact Study and Social-Economic Impact of BSE in Canada</i></p> <p>11:00 Josephine Smart, University of Calgary <i>Social-Economic Impacts of BSE in Alberta</i></p> <p>11:30 Patrick Feng, University of Calgary <i>Policy Convergence and Divergence</i></p>
12:00-1:00	Lunch

	<p>Prion Disease Risk Modeling Session Chair: Daniel Krewski, University of Ottawa</p> <p>1:00 David Cottrell, University of Ottawa <i>Risk Modeling for CJD</i></p> <p>1:20 Mustafa Al-Zoughool, University of Ottawa <i>Back Calculation Method for BSE</i></p>
	<p>Case Countries and Prion Disease Management Session Chair: Michael Tyshenko, University of Ottawa</p> <p>1:40 Nawal Farhat, University of Ottawa <i>Portugal Case Study</i></p> <p>2:00 Roxanne Lewis: University of Ottawa <i>Germany Case Study</i></p> <p>2:20 Mustafa Al-Zoughool: University of Ottawa <i>France Case Study</i></p> <p>2:40 Nataliya Karyakina, University of Ottawa <i>Russia Case Study</i></p> <p>3:00 Shalu Darshan, University of Ottawa <i>India Case Study</i></p>
3:20-3:35	Break
	<p>Prion Disease Risk Management Session Chair: Maura Ricketts, Public Health Agency of Canada</p> <p>3:35 Michael Tyshenko, University of Ottawa <i>What Can we Learn about Prion Disease Risk Management from Country Case Studies?</i></p> <p>4:00 William Leiss, University of Ottawa <i>An Integrated Risk Management Framework for Prion Diseases</i></p>
4:30	<i>Open Discussion</i>
5:00	Daniel Krewski, University of Ottawa <i>Summary and Conclusions</i>

Public Lecture
Tuesday 25th September, 18.00 – 19.30
Assembly Hall

Prof. James Ironside and Dr. Marc Turner will deliver presentations on vCJD, the current situation, risk of human to human spread and strategies to restrict the spread of vCJD.

Prof. James Ironside, who has been at the forefront of vCJD research from the outset, is Professor of Clinical Neuropathology at the University of Edinburgh and is the Head of the Neuropathology Laboratories in the National CJD Surveillance Unit. Prof. Ironside will present a lecture entitled “Beyond BSE - exploring the future of prion diseases in UK”

The second speaker, Dr. Marc Turner is a Clinical Director for the Scottish National Blood Transfusion Service and has a position as Associate Director of the Scottish Centre for Regenerative Medicine within the School of Clinical Sciences and Community Health. Dr. Turner will present a lecture entitled “Managing the risk of transmission of variant CJD by blood and tissues”

These presentations will be followed by an informed debate. It is hoped that these lectures and debate will provide a means by which the public can gain a greater understanding of vCJD and its risks of transmission and the measures in place to minimise that risk.

Wednesday 26 September 2007

Strathblane Hall

07.30 - 20.00

Congress Registration Open

Pentland / Sidlaw

08.45 - 10.00

Opening Ceremony

08.45 - 09.10

Opening Address

Professor Jean Manson, Neuropathogenesis Unit

09.10 - 09.30

Food and Blood Safety from Diagnosis to Decontamination Issues

Dr Jean-Phillipe Deslys, NeuroPrion

09.30 - 10.00

Opening Address

Professor Stanley Prusiner, University of California, San Francisco

10.00 - 10.30

Session 1 - Protein Misfolding

Chair: Prof Stanley Prusiner

S1.1

Prion Protein Aggregation, Amplification and Inhibition

Dr Byron Caughey

10.30 - 11.00

Tea/Coffee Break (*Cromdale Hall*)

sponsored by: **Idexx**

11.00 - 12.30

Session 1 - Protein Misfolding (cont)

Chair: Prof Stanley Prusiner

11.00 - 11.15 FC1.1

NMR and Fluorescence Structural Studies of an Anti-Prion Protein scFv Fragment

Mangels, C¹; Leliveld, RS²; Müller-Schiffmann, A²; Schweimer, K¹; Ziegler, J¹; Petsch, B³; Stitz, L³; Rösch, P¹; Korth, C²; Schwarzinger, S¹

¹University of Bayreuth, Germany; ²Heinrich-Heine-University, Germany; ³Friedrich-Löffler Institut, Germany

11.15 - 11.35 FC1.2

Limited Proteolysis of PrPSc: Alternating PK Resistant and Sensitive Segments Suggest a Beta Strand-turn-beta Strand Structural Core

Requena, JR¹; Sajnani, G¹; Pastrana, MA¹; Yeves, L¹; Onisko, B²; Dynin, I²

¹University of Santiago de Compostela, Spain; ²USDA, USA

11.35 - 11.55 FC1.3

In Vitro Amplification and Detection of Variant Creutzfeldt-Jakob Disease PrP^{Sc}

Jones, M¹; Peden, AH¹; Prowse, CV²; Groner, A³; Manson, JC⁴; Turner, ML⁵; Ironside, JW¹; MacGregor, IR²; Head, MW¹

¹University of Edinburgh, UK; ²Scottish National Blood Transfusion Service, UK; ³CSL Behring, Germany; ⁴Roslin Institute Neuropathogenesis Unit, UK; ⁵Royal Infirmary of Edinburgh, UK

11.55 - 12.10 FC1.4

Efficient in Vitro Conversion of CWD PrP-RES by Serial Protein Misfolding Cyclic Amplification

Kurt, T¹; Perrott, MR¹; Wilusz, CJ¹; Wilusz, J¹; Supattapone, S²; Telling, GC³; Zabel, MD¹; Hoover, EA¹

¹College of Veterinary Medicine and Biomedical Sciences, Colorado State University, USA; ²Dartmouth Medical School, USA; ³University of Kentucky, USA

12.10 - 12.30 FC1.5

Synthetic Prions from Recombinant Mouse Prion Protein with an Expanded Octarepeat Domain

Korth, C¹; Leliveld, R¹; Stitz, L²

¹Heinrich Heine University Duesseldorf, Germany; ²Friedrich-Loeffler Institute, Germany

12.30 - 14.30

12.30 - 13.30 **Bio-Rad
Satellite Symposium
Bio-Rad Innovations for TSEs
Diagnosis and Prevention**

Lunch/Poster Session (*Cromdale Hall*)

Wednesday 26 September 2007

14.30 - 16.05		Session 2 - Natural and Experimental Strains <i>Chair: Dr Jim Hope</i>
14.30 - 15.00	S2.1	Title (tbc) - Please refer to Programme Update <i>Prof John Collinge</i>
15.00 - 15.15	FC2.1	Discrimination of Prion Strains by the Cell Panel Assay <i>Mahal, SP; Demczyk, CA; Ercan, D; Weissmann, C</i> Scripps Florida, USA
15.15 - 15.30	FC2.2	In Vitro Prion Propagation of Prion Strains <i>Morales, R; Castilla, J; Saá, P; Soto, C</i> University of Texas Medical Branch, USA
15.30 - 15.45	FC2.3	Sporadic CJD Strain Classification by Transmission to Human Transgenic Mice <i>Bishop, M¹; Barron, R²; McConnell, I²; Head, M¹; Ironside, J¹; Will, R¹; Manson, J²</i> ¹ UK National CJD Surveillance Unit, UK; ² Roslin Institute / Neuropathogenesis Unit, UK
15.45 - 16.05	FC2.4	Prion Strain Interference in the Central Nervous System <i>Bartz, J¹; Bessen, R²; Kincaid, A¹</i> ¹ Creighton University, USA; ² Montana State University, USA
16.05 - 16.40		Tea/Coffee Break (Cromdale Hall) <i>sponsored by: Idexx</i>
16.40 - 18.00		Session 2 - Natural and Experimental Strains (cont) <i>Chair: Dr Jim Hope</i>
16.40 - 17.00	FC2.5	Extraneural Replication of Ruminant and Human Prions in Transgenic Mouse Models <i>Laude, H¹; Béringue, V¹; Le Dur, A¹; Reine, F¹; Chesnais, N¹; Fontés, M²; Vilotte, J-L¹</i> ¹ INRA, France; ² INSERM, France
17.00 - 17.20	FC2.6	Elements Modulating Transmission Barrier and Virulence in BSE-Derived Prions <i>Espinosa, JC¹; Andréoletti, O²; Herva, ME¹; Alamillo, E¹; Padilla, D¹; Lacroux, C²; Groschup, MH³; Torres, JM¹</i> ¹ CISA-INIA, Spain; ² INRA-ENVT, France; ³ FLI-INEID, Germany
17.20 - 17.35	FC2.7	Accelerated Studies of Interspecies Prion Transmission Using Combined Transgenic and PMCA Technologies <i>Green, KM¹; Castilla, J²; Seward, TS¹; Soto, C³; Telling, GC¹</i> ¹ University of Kentucky, USA; ² Scripps Research Institute, USA; ³ University of Texas Medical Branch, USA
17.35 - 17.50	FC2.8	Discrimination of Two Prion Strains in Cell Culture at a Stage Preceding Replication <i>Browning, SR; Mahal, SP; Baker, CA; Smith, EW; Demczyk, CA; Weissmann, C</i> Scripps Research Institute, USA

Cromdale Hall

18.00 - 20.00 **Welcome Reception / Poster Party**

Thursday 27 September 2007

Strathblane Hall

08.00 - 18.30

Congress Registration Open

Pentland

Sidlaw

09.00 - 10.30

Session 3 - Pathology and Pathogenesis

Chair: Prof James Ironside

Session 5 - Epidemiology, Risk Assessment and Transmission

Chair: Prof Maura Ricketts

09.00 - 09.30

S3.1

Cellular Pathology of Prion Diseases

Dr. Martin Jeffrey

S5.1

Variant Creutzfeldt-Jakob Disease: A Critical Review of Residual Uncertainty

Prof. Robert Will

09.30 - 09.50

FC3.1

Dynamics and Distribution of Infectivity in Sheep Blood

Andreoletti, O¹; Morel, N²; Lacroux, C¹; Simon, S²; Mathey, J¹; Lantier, I³; Rouillon, V¹; Delmas, JM¹; Weissbecker, JL⁴; Corbière, F¹; Simmons, H⁵; Schelcher, F¹; Lantier, F³; Grassi, J²

¹ENVT, France; ²iBiTec-S, Service de Pharmacologie et d'Immunoanalyse, CEA/Saclay, France; ³Centre Inra de Tours, France; ⁴Domaine Expérimental de Langlade, France; ⁵ASU, UK

FC5.2

Prevalence of Abnormal Prion Protein in the Population of Great Britain (GB) - Initial Results from Large-scale Tonsil Testing

Kelly, C¹

¹Health Protection Agency Centre for Infections, UK;

09.50 - 10.10

FC3.2

Investigating the Subcellular Location of the Infectious "Prion" and its Relationship to PrPres in a Cell Culture Model of Prion Disease

Lewis, V¹; Lawson, VA¹; Masters, CL²; Hill, Andrew F³; Collins, Steven J¹

¹University of Melbourne, Australia; ²Mental Health Research Institute of Victoria, Australia; ³Bio21 Molecular Science & Biotechnology Institute, Australia

FC5.1

Transmission Studies in Primates.

A presentation by Paul Brown combining the following two papers:

FC5.1.1

Transmission Results in Squirrel Monkeys Inoculated with Human sCJD, vCJD, and GSS Blood Specimens: the Baxter Study

Brown, P¹; Gibson, S²; Williams, L³; Ironside, J⁴; Will, R⁴; Kreil, T⁵; Abee, C³

¹Fondation Alliance BioSecure, France; ²University of South Alabama, USA; ³University of Texas MD Anderson Cancer Center, USA; ⁴Western General Hospital, UK; ⁵Baxter BioScience, Austria

FC5.1.2

Interim Transmission Results in Cynomolgus Macaques Inoculated with BSE and vCJD Blood Specimens

Lasmezas, C¹; Lescoutra, N²; Comoy, E²; Holznagel, E³; Loewer, J³; Motzkus, D⁴; Hunsmann, G⁴; Ingrosso, L⁵; Bierke, P⁶; Pocchiari, M⁶; Ironside, J⁷; Will, R⁷; Deslys, J-P²

¹Scripps Florida, Infectology, USA; ²CEA, France; ³PEI, Germany; ⁴DPZ, Germany; ⁵Istituto Superiore di Sanita, Italy; ⁶SMI, Sweden; ⁷CJD Surveillance Unit, UK

10.10 - 10.30

FC3.3

Host PrP Glycosylation; A Major Factor Determining the Outcome of Transmissible Spongiform Encephalopathy Infection

Cancellotti, E¹; Baybutt, H¹; Blackford, L¹; Bradford, B¹; Piccardo, P²; Plinston, C¹; Hart, P¹; Barron, RM¹; Manson, JC¹; Tuzi, NL¹

¹Neuropathogenesis Unit, Roslin Institute, UK; ²Centre for Biologics Evaluation and Research, Food and Drug Administration, USA

FC5.3

Assessing the Risk of vCJD Transmission by Dentistry; Distribution of Infectivity in Oral Tissues of VM Mice after Simulated Oral Feeding of BSE-301V

Sutton, JM¹; Kirby, E¹; Dickinson, J¹; Dennis, M¹; Cornwall, M¹; Vassey, MJ¹; Smith, A²; Marsh, PD¹; Walker, JT¹; Raven, NDH¹

¹Health Protection Agency, Centre for Emergency Preparedness and Response, UK; ²University of Glasgow, UK

10.30 - 11.00

Tea/Coffee Break (Cromdale Hall)

sponsored by: Idexx

Pentland		Sidlaw	
11.00 - 12.40	Session 3 - Pathology and Pathogenesis (cont) <i>Chair: Prof James Ironside</i>		Session 5 - Epidemiology, Risk Assessment and Transmission (cont) <i>Chair: Prof Maura Ricketts</i>
11.00 - 11.20	FC3.4 The Role of the Neuromuscular Junction in Prion Agent Infection of Muscle Cells: A Model for Transynaptic Spread of the Prion Agent <i>Bessen, RA.; Dlakic, W; Martinka, S; DeJoia, C</i> Montana State University, USA	FC5.4	A Systematic Review of Therapeutic Interventions for Human Prion Disease <i>Knight, R¹; Stewart, L²; Rydzewska, L³; Keogh, G⁴; Chalmers, I⁵; Firkins, L³; Walker, S³</i> ¹ NCJDSU, UK; ² MRC CTU, UK; ³ MRC, UK; ⁴ National Prion Clinic, UK; ⁵ UK
11.20 - 11.40	FC3.5 Granulomas Induce Prion replication Competence Independent of Follicular Dendritic Cells <i>Heikenwälder, M¹; Margalith, I²; Julius, C²; Polymenidou, M²; Haybäck, J²; Marcel, A²; Schwarz, P²; Kurrer, M²; Aguzzi, A²</i> ¹ University Hospital Zürich, Switzerland; ² Pathology, Switzerland	FC5.5	The Disease Phenotype of BASE Strain in Cattle and its Molecular Fingerprints in Non-human Primates A presentation by Gianluigi Zanusso combining the following two papers:
		FC5.5.1	BASE Transmitted to Primates and MV2 sCJD Subtype Share PrP27-30 and PrPSc C-terminal Truncated Fragments <i>Zanusso, G¹; Comroy, E²; Fasoli, E¹; Fiorini, M¹; Lescoutra, N³; Ruchoux, MM³; Casalone, C⁴; Caramelli, M⁴; Ferrari, S¹; Lasmezas, C⁵; Deslys, J-P³; Monaco, S¹</i> ¹ University of Verona; ² CEA, IMETI/SEPIA; ³ IMETI/SEPIA; ⁴ IZSPLVA; ⁵ The Scripps Research Institute
		FC5.5.2	Transmission of Italian BSE and BASE Isolates in Cattle Results into a Typical BSE Phenotype and a Muscle Wasting Disease <i>Zanusso, G¹; Lombardi, G²; Casalone, C³; D'Angelo, A⁴; Gelmetti, D²; Torcoli, G²; Barbieri, I²; Corona, C³; Fasoli, E¹; Farinazzo, A¹; Fiorini, M¹; Gelati, M¹; Iulini, B³; Tagliavini, F³; Ferrari, S¹; Monaco, S¹; Caramelli, M³; Capucci, L²</i> ¹ University of Verona; ² IZSLER; ³ IZSPLVA; ⁴ University of Turin; ⁵ Isituto Carlo Besta
11.40 - 12.00	FC3.6 Role of the GALT in Scrapie Agent Neuroinvasion from the Intestine <i>Mabbott, N; Glaysher, B</i> Roslin Institute, UK	FC5.6	Atypical and Classical Scrapie in Sheep: Prevalence Estimates from Healthy Slaughter and Fallen Stock Surveillance Programmes in 20 European Countries <i>Fediaevsky, A¹; Tongue, SC²; Nöremark, M³; Hopp, P⁴</i> ¹ AFSSA, France; ² CERA, VLA Weybridge, UK; ³ SVA, National Veterinary Institute, Sweden; ⁴ National Veterinary Institute, Norway
12.00 - 12.20	FC3.7 The Immune System Facilitates BSE Transmission into Mice <i>Farquhar, CF; Brown, KL; McConnell, I; Boyle, A; Mabbott, NA; Bruce, ME</i> Neuropathogenesis Unit, RI, UK	FC5.7	Precipitation of Prion Protein Facilitates Formation and Removal of High Molecular Aggregates <i>Gröner, A; Schäfer, W</i> CSL Behring, Germany

Thursday 27 September 2007

Pentland		Sidlaw
12.20 - 12.40	Session 3 - Pathology and Pathogenesis (cont) <i>Chair: Prof James Ironside</i>	Session 5 - Epidemiology, Risk Assessment and Transmission (cont) <i>Chair: Prof Maura Ricketts</i>
12.20 - 12.40 FC3.8	Immunotherapeutic Effect of Anti-PrP Monoclonal Antibodies on TSE Mouse Models: Pharmacodynamic and Pharmacokinetic Analysis <i>Feraudet, C¹; Andreoletti, O²; Morel, N²; Chouaf-Lakhdar, L³; Mathey, J¹; Simon, S²; Lacroux, C¹; Vollad, H²; Lamourette, P²; Betemps, D³; Frobert, Y²; Torres, JM⁴; Creminon, C²; Baron, T³; Grassi, J²</i> ¹ INRA (UMR INRA/ENVT 1225), France; ² CEA Saclay, France; ³ AFSSA Lyon, France; ⁴ INIA, Spain	FC5.8 Assessment of Direct and Indirect Transmission of CWD from Three Cervid Species to Humans <i>Kong, Q¹; Zheng, M¹; Qing, L¹; Huang, S¹; Chen, F¹; Wang, M¹; Wang, L¹; Miller, M²; Hamir, AN³; Richt, JA³; O'Rourke, K⁴; Belay, ED⁵; Schonberger, LB⁵; Gambetti, P¹;</i> ¹ Case Western Reserve University, USA; ² Colorado Division of Wild Life, USA; ³ USDA, USA; ⁴ USDA ARS, USA; ⁵ Centers for Disease Control and Prevention, USA
12.40 - 13.40	DuPont Satellite Symposium Development and Validation of a Detergent Enzyme Reagent for Effective Prion Decontamination	Abbott Satellite Symposium Workflow Improvements and Cost Savings through Implementation of Automation into TSE Screening Laboratories
12.40 - 14.30 Lunch / Poster Session (Cromdale Hall)		
14.30 - 16.00	Session 4 - Protein Misfolding 2 <i>Chair: Prof Roger Morris</i>	Session 6 - IPFA Session Progress With Blood Safety and Prions <i>Chairs: Paul Brown & Marc Turner</i> Sponsored by: Aicon AG, Microsens & MacoPharma
14.30 - 15.00 S4.1	Induction of Cerebral β-Amyloidosis in Transgenic Mice <i>Prof Mathias Jucker</i>	14.30 - 14.40 Introduction & Opening Remarks <i>Turner, M</i> UK
15.00 - 15.20 FC4.1	A Novel Sorting Nexin (SNX33) Interferes with Prion Infection by Modulation of PrP^c Shedding <i>Nunziante, M¹; Heiseke, A¹; Lichtenthaler, S²; Vorberg, I¹; Schätzl, HM¹;</i> ¹ Institute of Virology, Germany; ² Adolf-Butenandt-Institute, Germany	14.40 - 15.05 Update on Prospective Studies of vCJD prevalence in the UK <i>Gill, N</i> UK
15.20 - 15.40 FC4.2	Cellular Prion Protein Overexpression Promotes Prion-Like Conformations in Transgenic Mice and Transfected Cells <i>Bellon, A¹; Solfrosi, L¹; Schaller, M¹; Abalos, G¹; Cruite, J¹; Laude, H²; Williamson, RA¹</i> ¹ The Scripps Research Institute, USA; ² INRA, France	15.05 - 15.30 Prion Removal Devices: Assessment of Current Technologies <i>Prowse, C</i> UK
15.40 - 16.00 FC4.3	Transmission of AA-amyloidosis: Similarities with Prion Disorders <i>Westermark, P</i> Rudbeck laboratory, Sweden	15.30 - 16.00 Current Status of PrP Blood Screening Tests. Announcement of Fondation Alliance BioSecure (FAB) Grant Awards for 2007/8 <i>Brown, P</i> USA
16.00 - 16.30 Tea/Coffee Break (Cromdale Hall) sponsored by: Idexx		

Thursday 27 September 2007

Pentland		Sidlaw
16.30 - 18.00	Session 4 - Protein Misfolding 2 (cont) Chair: Prof Roger Morris	Session 6 - IPFA Session (cont) Progress With Blood Safety and Prions Chairs: Paul Brown & Marc Turner
16.30 - 16.50 FC4.4	Disease-associated Prion Protein Oligomers Inhibit the 26S Proteasome <i>Tabrizi, SJ¹; Kristiansen, M¹; Deriziotis, P¹; Dimcheff, DE²; Jackson, GS¹; Ovaa, H³; Naumann, H¹; Clarke, AR¹; van Leeuwen, FWB³; Menendez-Benito, V⁴; Dantuma, NP⁴; Portis, JL²; Collinge, J¹;</i> ¹ Institute of Neurology, UK; ² NIAID, NIH Rocky Mountain Laboratories, USA; ³ Netherlands Cancer Institute, Netherlands; ⁴ Karolinska Institutet, Sweden	16.30 - 16.55 Developing Views and Regulatory Progress for Screening Tests <i>Minor, P</i> UK
16.50 - 17.10 FC4.5	Induction of Cellular Autophagy Reduces Prions <i>Heiseke, A; Ertmer, A; Gilch, S; Schätzl, HM;</i> Institute of Virology, Germany	16.55 - 17.20 vCJD Risk Reduction Measures in the Context of Overall Blood Safety <i>Dobra, S</i> UK
17.10 - 17.30 FC4.6	Revertant Subclones Derived from Highly Susceptible Cells as a Tool for the Identification of Susceptibility Factors <i>Klohn, P.-C.¹; Alden, J.¹; Grigoriadis, A.²; Jat, P.¹; Collinge, J.¹;</i> ¹ Institute of Neurology, UK; ² Ludwig Institute for Cancer Research, UK	17.20 - 17.35 vCJD and Transfusion Safety: Update from France <i>Coste, J</i> France
17.30 - 17.45 FC4.7	Hsp70 Prevents PrP Misfolding and Protects Drosophila Neurons Against PrP Neurotoxicity <i>Rincon-Limas, D¹; Casas-Tinto, S¹; Nino-Rosales, ML¹; Gomez-Velazquez, M¹; Castilla, J²; Soto, C¹; Fernandez-Funez, P¹;</i> ¹ University of Texas Medical Branch, USA; ² Scripps Research Institute, USA	17.35 - 18.00 Discussion
17.45 - 18.00 FC4.8	A Critical Role for Heat Shock Factor 1 in Prion Pathogenesis <i>Steele, A¹; Jackson, W¹; Hutter, G²; Aguzzi, A²; King, O¹; Raymond, G³; Caughey, B³; Lindquist, S¹;</i> ¹ Whitehead Institute/MIT, USA; ² University Hospital, Zurich, Switzerland; ³ Rocky Mountain Labs, NIAID, NIH, USA	  
Royal Museum		
19.00 - 23.30	Gala Dinner	

Friday 28 September 2007

Strathblane Hall

08.00 - 13.00

Congress Registration Open

Pentland / Sidlaw

Harris 1

09.00 - 10.00

Poster Prize Winner Presentations

Families Discussion

10.00 - 10.30

International Alliance of Families Session
The CJD International Alliance, Working Together Globally as CJD Patient and Family Representatives
Suzanne Solvyns
 The CJD Support Network, Australia
Florence Kranitz
 The CJD Foundation, USA

10.30 - 11.00

Tea/Coffee Break (Cromdale Hall)

sponsored by: Idexx

11.00 - 12.40

Session 7 - Hot Topics
Chair: Prof Jean Mason

11.00 - 11.20

FC7.1

Title (tbc) - Please refer to Programme Update
Collinge, J

11.20 - 11.40

FC7.2

Enzymatic Degradation of PrP^{Sc} Fails to Dis-Infect Bovine BSE Brain Homogenates
Langeveld, J¹; Groschup, MH²; Buschmann, A²; Becher, D³; Wang, JJ⁴; Shih, JCH⁵
¹CIDC-Lelystad, Netherlands; ²Friedrich-Loeffler-Institut (FLI-INEID), Germany; ³Micromun GmbH, Germany; ⁴BioResource International, USA; ⁵North Carolina State University, USA

11.40 - 12.00

FC7.3

An Increase in PrP²⁰ Precedes Prion Accumulation
Zou, W; Yuan, J; Dong, Z; Guo, JP; McGeeham, J; Xiao, X; Wang, J; Cali, I; Kneale, G; McGreer, PL; Petersen, R; Gambetti, P
 Case Western Reserve University, USA

12.00 - 12.20

FC7.4

De Novo Generation of Prions in a Cell-free System
Castilla, J¹; Nonno, R²; Fernández-Borges, N¹; Di Bari, MA²; Cosseddu, GM²; de Castro, J¹; Chiappini, B²; Vaccari, G²; Agrimi, U²
¹Scripps Florida, USA; ²Istituto Superiore di Sanità, Italy

12.20 - 12.40

FC7.5

Prions in Plasma of Patients with Sporadic Creutzfeldt-Jakob Disease
Safar, J.G^{1,3}; Geschwind, M.D^{2,3}; Letessier, F¹; Kuo, A¹; Pomeroy, K¹; Deering, C¹; Serban, A¹; Groth, D¹; Miller, B.L^{2,3}; DeArmond, S.J^{1,4}; Prusiner, S.B^{1,3,5}
¹Institute for Neurodegenerative Diseases, ²Memory and Aging Center, Departments of ³Neurology, ⁴Pathology, and ⁵Biochemistry and Biophysics, University of California, San Francisco, California 94143

12.40 - 12.45

Closing Ceremony
Prof Jean Manson

12.45 - 12.50

Prion 2008 Representative